253 related articles for article (PubMed ID: 33569057)
1. Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer.
Duan R; Li X; Zeng D; Chen X; Shen B; Zhu D; Zhu L; Yu Y; Wang D
Front Immunol; 2020; 11():609337. PubMed ID: 33569057
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
3. Perineural Invasion and Postoperative Adjuvant Chemotherapy Efficacy in Patients With Gastric Cancer.
Tao Q; Zhu W; Zhao X; Li M; Shu Y; Wang D; Li X
Front Oncol; 2020; 10():530. PubMed ID: 32373527
[No Abstract] [Full Text] [Related]
4. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
5. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
6. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.
Yan H; Chen Y; Yang Z; Li Z; Che X; Xiao J; Liu Y; Qu X
Front Immunol; 2020; 11():621623. PubMed ID: 33613554
[TBL] [Abstract][Full Text] [Related]
7. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Lee J; Park CK; Park JO; Lim T; Park YS; Lim HY; Lee I; Sohn TS; Noh JH; Heo JS; Kim S; Lim DH; Kim KM; Kang WK
Clin Cancer Res; 2008 Jan; 14(1):82-8. PubMed ID: 18172256
[TBL] [Abstract][Full Text] [Related]
8. Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer.
Dai D; Zhao X; Li X; Shu Y; Shen B; Chen X; Chen D; Wang D
Front Oncol; 2019; 9():1452. PubMed ID: 31970085
[No Abstract] [Full Text] [Related]
9. Immune infiltration profiling in gastric cancer and their clinical implications.
Ren F; Zhao Q; Zhao M; Zhu S; Liu B; Bukhari I; Zhang K; Wu W; Fu Y; Yu Y; Tang Y; Zheng P; Mi Y
Cancer Sci; 2021 Sep; 112(9):3569-3584. PubMed ID: 34251747
[TBL] [Abstract][Full Text] [Related]
10. Gastric cancer immune microenvironment score predicts neoadjuvant chemotherapy efficacy and prognosis.
Zhao S; Liu Y; Ding L; Zhang C; Ye J; Sun K; Song W; Cai S; He Y; Peng J; Xu J
J Pathol Clin Res; 2024 May; 10(3):e12378. PubMed ID: 38778559
[TBL] [Abstract][Full Text] [Related]
11. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
14. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi J; Lim H; Nam DK; Kim HS; Cho DY; Yi JW; Kim HC; Cho YK; Kim MW; Joo HJ; Lee KB; Kim KB
Br J Cancer; 2001 Jan; 84(2):186-92. PubMed ID: 11161374
[TBL] [Abstract][Full Text] [Related]
15. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.
Wang JB; Gao YX; Ye YH; Zheng QL; Luo HY; Wang SH; Zhang T; Jin QW; Zheng CH; Li P; Lin JX; Chen QY; Cao LL; Yang YH; Huang CM; Xie JW
Theranostics; 2024; 14(7):2915-2933. PubMed ID: 38773976
[No Abstract] [Full Text] [Related]
17. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
[TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.
Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730
[TBL] [Abstract][Full Text] [Related]
19. Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil.
Tajima Y; Shimoda T; Nakanishi Y; Yokoyama N; Tanaka T; Shimizu K; Saito T; Kawamura M; Kusano M; Kumagai K
J Cancer Res Clin Oncol; 2003 Dec; 129(12):683-90. PubMed ID: 14576935
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
